Retour

Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024

Calendar Calendar of Events

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.

GlobeNewswire Inc. • 07/05/2024 à 12:55:00
Asensus Surgical, Inc.
Address: 1 TW ALEXANDER DRIVE
Postal Code: 27703
City: DURHAM
State: NC
Phone Number: 919-765-8400
Website: https://www.asensus.com
Status: Active
Company Info

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

List Date1991-08-01
MarketStocks
LocalUS
Primary ExchangeXASE
TypeCS
Currency NameUSD
CIK0000876378
Composite figiBBG000C1XKW7
Share Class figiBBG001S696K8
Market Cap70,806,236 USD
SIC Code3841
SIC DescriptionSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Total Employees209
Share Class Shares Outstanding272330000
Weighted Shares Outstanding272331675
Round Lot100
Updated date2024-05-19
Stats
Last 5 days
17-05
16-05
15-05
14-05
13-05
Last
0.265
0.261
0.252
0.253
0.277
Variance
1.53%
3.16%
-9.68%
-8.66%
1.84%
Open
0.261
0.253
0.279
0.277
0.272
Highest
0.278
0.265
0.279
0.285
0.277
Lowest
0.278
0.265
0.278
0.285
0.277
History
PeriodVarhighestlowest
1 week
-2.57%
0.277
0.265
1 month
2.71%
0.26
0.248
3 month
-10.77%
0.306
0.225
6 month
13.54%
0.2374
0.225
1 year
-52.99%
0.5867
0.204
3 year
-86.75%
2.06
0.204
5 year
-93.22%
4.05
0.204
10 year
-93.22%
4.05
0.204
Stock Financials
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-14 UNPUB
Assets 96,523,000 78,371,000 70,727,000 UNPUB
Current Assets 71,556,000 54,910,000 45,932,000 UNPUB
Current Liabilities 10,877,000 10,647,000 12,123,000 UNPUB
Equity 79,717,000 61,503,000 47,253,000 UNPUB
Equity Attributable To Noncontrolling Interest 0 0 0 UNPUB
Equity Attributable To Parent 79,717,000 61,503,000 47,253,000 UNPUB
Liabilities 16,806,000 16,868,000 23,474,000 UNPUB
Liabilities And Equity 96,523,000 78,371,000 70,727,000 UNPUB
Noncurrent Assets 24,967,000 23,461,000 24,795,000 UNPUB
Noncurrent Liabilities 5,929,000 6,221,000 11,351,000 UNPUB
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-14 UNPUB
Exchange Gains/Losses 403,000 348,000 -1,217,000 UNPUB
Net Cash Flow 12,409,000 -10,850,000 14,255,000 UNPUB
Net Cash Flow, Continuing 12,006,000 -11,198,000 15,472,000 UNPUB
Net Cash Flow From Financing Activities -483,000 194,000 9,743,000 UNPUB
Net Cash Flow From Financing Activities, Continuing -483,000 194,000 9,743,000 UNPUB
Net Cash Flow From Investing Activities 29,737,000 6,564,000 20,778,000 UNPUB
Net Cash Flow From Investing Activities, Continuing 29,737,000 6,564,000 20,778,000 UNPUB
Net Cash Flow From Operating Activities -17,248,000 -17,956,000 -15,049,000 UNPUB
Net Cash Flow From Operating Activities, Continuing -17,248,000 -17,956,000 -15,049,000 UNPUB
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-14 UNPUB
Comprehensive Income/Loss -21,361,000 -20,388,000 -18,891,000 UNPUB
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Comprehensive Income/Loss Attributable To Parent -21,361,000 -20,388,000 -18,891,000 UNPUB
Other Comprehensive Income/Loss 857,000 274,000 -573,000 UNPUB
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2023-05-11 2023-08-10 2023-11-14 UNPUB
Basic Earnings Per Share 0 0 0 UNPUB
Benefits Costs and Expenses 23,103,000 21,755,000 19,350,000 UNPUB
Cost Of Revenue 2,947,000 3,074,000 2,869,000 UNPUB
Costs And Expenses 23,103,000 21,755,000 19,350,000 UNPUB
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit -1,971,000 -1,993,000 -1,780,000 UNPUB
Income/Loss From Continuing Operations After Tax -22,218,000 -20,662,000 -18,318,000 UNPUB
Income/Loss From Continuing Operations Before Tax -22,127,000 -20,674,000 -18,261,000 UNPUB
Income Tax Expense/Benefit 91,000 -12,000 57,000 UNPUB
Interest Expense, Operating 0 0 0 UNPUB
Net Income/Loss -22,218,000 -20,662,000 -18,318,000 UNPUB
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 UNPUB
Net Income/Loss Attributable To Parent -22,218,000 -20,662,000 -18,318,000 UNPUB
Net Income/Loss Available To Common Stockholders, Basic -22,218,000 -20,662,000 -18,318,000 UNPUB
Operating Expenses 20,377,000 18,870,000 18,479,000 UNPUB
Operating Income/Loss -22,348,000 -20,863,000 -20,259,000 UNPUB
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 UNPUB
Preferred Stock Dividends And Other Adjustments 0 0 0 UNPUB
Revenues 976,000 1,081,000 1,089,000 UNPUB
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-10 2023-03-02
Assets 166,560,000 147,350,000 128,653,000 116,053,000
Current Assets 118,684,000 108,562,000 103,530,000 86,873,000
Current Liabilities 8,653,000 9,682,000 9,844,000 10,414,000
Equity 150,825,000 131,439,000 112,976,000 99,645,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 150,825,000 131,439,000 112,976,000 99,645,000
Liabilities 15,735,000 15,911,000 15,677,000 16,408,000
Liabilities And Equity 166,560,000 147,350,000 128,653,000 116,053,000
Noncurrent Assets 47,876,000 38,788,000 25,123,000 29,180,000
Noncurrent Liabilities 0 0 5,833,000 5,994,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-10 2023-03-02
Exchange Gains/Losses -45,000 284,000 -539,000 -81,000
Net Cash Flow 6,721,000 -13,870,000 2,843,000 -11,813,000
Net Cash Flow, Continuing 6,766,000 -14,154,000 3,382,000 -11,732,000
Net Cash Flow From Financing Activities -336,000 5,000 -1,000 -332,000
Net Cash Flow From Financing Activities, Continuing -336,000 5,000 -1,000 -332,000
Net Cash Flow From Investing Activities 23,045,000 128,000 18,037,000 47,537,000
Net Cash Flow From Investing Activities, Continuing 23,045,000 128,000 18,037,000 47,537,000
Net Cash Flow From Operating Activities -15,943,000 -14,287,000 -14,654,000 -58,937,000
Net Cash Flow From Operating Activities, Continuing -15,943,000 -14,287,000 -14,654,000 -58,937,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-10 2023-03-02
Comprehensive Income/Loss -20,330,000 -21,476,000 -20,493,000 -77,685,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -20,330,000 -21,476,000 -20,493,000 -77,685,000
Other Comprehensive Income/Loss -1,202,000 -1,857,000 -1,569,000 -2,124,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2022-05-04 2022-08-08 2022-11-10 2023-03-02
Basic Earnings Per Share 0 0 0 0
Benefits Costs and Expenses 20,110,000 20,528,000 21,432,000 82,330,000
Cost Of Revenue 1,823,000 2,347,000 4,404,000 10,872,000
Costs And Expenses 20,110,000 20,528,000 21,432,000 82,330,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit -757,000 -1,353,000 -1,841,000 -3,785,000
Income/Loss From Continuing Operations After Tax -19,128,000 -19,619,000 -18,924,000 -75,561,000
Income/Loss From Continuing Operations Before Tax -19,044,000 -19,534,000 -18,869,000 -75,243,000
Income Tax Expense/Benefit 84,000 85,000 55,000 318,000
Interest Expense, Operating 200,000 141,000 99,000 410,000
Net Income/Loss -19,128,000 -19,619,000 -18,924,000 -75,561,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -19,128,000 -19,619,000 -18,924,000 -75,561,000
Net Income/Loss Available To Common Stockholders, Basic -19,128,000 -19,619,000 -18,924,000 -75,561,000
Operating Expenses 18,196,000 18,214,000 17,191,000 71,894,000
Operating Income/Loss -18,953,000 -19,567,000 -19,032,000 -75,679,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 1,066,000 994,000 2,563,000 7,087,000
Balance Sheet
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-05 2021-11-03 2022-02-28
Assets 223,615,000 212,004,000 199,759,000 186,473,000
Current Assets 182,325,000 174,007,000 134,807,000 113,297,000
Current Liabilities 9,508,000 8,307,000 9,421,000 9,850,000
Equity 205,918,000 195,561,000 181,501,000 169,246,000
Equity Attributable To Noncontrolling Interest 0 0 0 0
Equity Attributable To Parent 205,918,000 195,561,000 181,501,000 169,246,000
Liabilities 17,697,000 16,443,000 18,258,000 17,227,000
Liabilities And Equity 223,615,000 212,004,000 199,759,000 186,473,000
Noncurrent Assets 41,290,000 37,997,000 64,952,000 73,176,000
Noncurrent Liabilities 0 0 8,837,000 7,377,000
Cash Flow Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-05 2021-11-03 2022-02-28
Exchange Gains/Losses -108,000 -221,000 148,000 376,000
Net Cash Flow 148,865,000 -8,271,000 -97,191,000 1,754,000
Net Cash Flow, Continuing 148,973,000 -8,050,000 -97,339,000 1,378,000
Net Cash Flow From Financing Activities 159,605,000 503,000 33,000 161,705,000
Net Cash Flow From Financing Activities, Continuing 159,605,000 503,000 33,000 161,705,000
Net Cash Flow From Investing Activities -395,000 -305,000 -88,370,000 -119,668,000
Net Cash Flow From Investing Activities, Continuing -395,000 -305,000 -88,370,000 -119,668,000
Net Cash Flow From Operating Activities -10,237,000 -8,248,000 -9,002,000 -40,659,000
Net Cash Flow From Operating Activities, Continuing -10,237,000 -8,248,000 -9,002,000 -40,659,000
Comprehensive Income
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-05 2021-11-03 2022-02-28
Comprehensive Income/Loss -19,278,000 -12,700,000 -17,053,000 -65,694,000
Comprehensive Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Comprehensive Income/Loss Attributable To Parent -19,278,000 -12,700,000 -17,053,000 -65,694,000
Other Comprehensive Income/Loss -1,938,000 472,000 -984,000 -3,232,000
Other Comprehensive Income/Loss Attributable To Parent UNPUB UNPUB UNPUB UNPUB
Income Statement
LabelQuarter 1 (USD)Quarter 2 (USD)Quarter 3 (USD)Full Year (USD)
Filing date 2021-05-11 2021-08-05 2021-11-03 2022-02-28
Basic Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Benefits Costs and Expenses 19,461,000 14,272,000 18,608,000 70,469,000
Cost Of Revenue 3,112,000 2,347,000 3,350,000 11,096,000
Costs And Expenses 19,461,000 14,272,000 18,608,000 70,469,000
Diluted Earnings Per Share UNPUB UNPUB UNPUB UNPUB
Gross Profit -1,029,000 -1,245,000 -779,000 -2,864,000
Income/Loss From Continuing Operations After Tax -17,340,000 -13,172,000 -16,069,000 -62,462,000
Income/Loss From Continuing Operations Before Tax -17,378,000 -13,170,000 -16,037,000 -62,237,000
Income Tax Expense/Benefit -38,000 2,000 32,000 225,000
Interest Expense, Operating 7,000 5,000 65,000 370,000
Net Income/Loss -17,340,000 -13,172,000 -16,069,000 -62,462,000
Net Income/Loss Attributable To Noncontrolling Interest 0 0 0 0
Net Income/Loss Attributable To Parent -17,340,000 -13,172,000 -16,069,000 -62,462,000
Net Income/Loss Available To Common Stockholders, Basic -17,340,000 -13,172,000 -16,069,000 -62,462,000
Operating Expenses 14,384,000 14,839,000 16,659,000 61,755,000
Operating Income/Loss -15,413,000 -16,084,000 -17,438,000 -64,619,000
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic 0 0 0 0
Preferred Stock Dividends And Other Adjustments 0 0 0 0
Revenues 2,083,000 1,102,000 2,571,000 8,232,000
Calendar
17 May 2024 (Time UTC) Actual Previous Consensus
★
15:30
United States
-17800.000
★
15:30
United States
-60000.000
★
15:30
United States
53700.000
★
15:30
United States
-135800.000
★★
15:30
United States
4400.000
★
15:30
United States
215400.000
★
15:30
United States
-31400.000
★
15:30
United States
62600.000
★
15:30
United States
1300.000
★
15:30
United States
-9700.000
★
15:30
United States
199600.000
★★
15:30
United States
★
15:30
United States
★
15:30
United States
★
15:30
United States
Options
Ticker
CFI
Contract Type
Exercise Style
Share Per Contract
Strike Price
Primary Exchange
Expiration Date
O:ASXC240517P00007500 OPASPS Put American 100 7.5 BATO 2024-05-17
O:ASXC240517P00005000 OPASPS Put American 100 5 BATO 2024-05-17
O:ASXC240517P00002500 OPASPS Put American 100 2.5 BATO 2024-05-17
O:ASXC240517P00002000 OPASPS Put American 100 2 BATO 2024-05-17
O:ASXC240517P00001500 OPASPS Put American 100 1.5 BATO 2024-05-17
O:ASXC240517P00001000 OPASPS Put American 100 1 BATO 2024-05-17
O:ASXC240517P00000500 OPASPS Put American 100 0.5 BATO 2024-05-17
O:ASXC240517C00007500 OCASPS Call American 100 7.5 BATO 2024-05-17
O:ASXC240517C00005000 OCASPS Call American 100 5 BATO 2024-05-17
O:ASXC240517C00002500 OCASPS Call American 100 2.5 BATO 2024-05-17
O:ASXC240517C00002000 OCASPS Call American 100 2 BATO 2024-05-17
O:ASXC240517C00001500 OCASPS Call American 100 1.5 BATO 2024-05-17
O:ASXC240517C00001000 OCASPS Call American 100 1 BATO 2024-05-17
O:ASXC240517C00000500 OCASPS Call American 100 0.5 BATO 2024-05-17
O:ASXC240419P00007500 OPASPS Put American 100 7.5 BATO 2024-04-19
O:ASXC240419P00005000 OPASPS Put American 100 5 BATO 2024-04-19
O:ASXC240419P00002500 OPASPS Put American 100 2.5 BATO 2024-04-19
O:ASXC240419P00002000 OPASPS Put American 100 2 BATO 2024-04-19
O:ASXC240419C00007500 OCASPS Call American 100 7.5 BATO 2024-04-19
O:ASXC240419P00001500 OPASPS Put American 100 1.5 BATO 2024-04-19
O:ASXC240419P00001000 OPASPS Put American 100 1 BATO 2024-04-19
O:ASXC240419P00000500 OPASPS Put American 100 0.5 BATO 2024-04-19
O:ASXC240419C00005000 OCASPS Call American 100 5 BATO 2024-04-19
O:ASXC240419C00002000 OCASPS Call American 100 2 BATO 2024-04-19
O:ASXC240419C00001500 OCASPS Call American 100 1.5 BATO 2024-04-19
O:ASXC240419C00001000 OCASPS Call American 100 1 BATO 2024-04-19
O:ASXC240419C00002500 OCASPS Call American 100 2.5 BATO 2024-04-19
O:ASXC240419C00000500 OCASPS Call American 100 0.5 BATO 2024-04-19
O:ASXC240315P00002000 OPASPS Put American 100 2 BATO 2024-03-15
O:ASXC240315P00001500 OPASPS Put American 100 1.5 BATO 2024-03-15
O:ASXC240315P00001000 OPASPS Put American 100 1 BATO 2024-03-15
O:ASXC240315P00000500 OPASPS Put American 100 0.5 BATO 2024-03-15
O:ASXC240315C00002000 OCASPS Call American 100 2 BATO 2024-03-15
O:ASXC240315C00001500 OCASPS Call American 100 1.5 BATO 2024-03-15
O:ASXC240315C00001000 OCASPS Call American 100 1 BATO 2024-03-15
O:ASXC240315C00000500 OCASPS Call American 100 0.5 BATO 2024-03-15
O:ASXC240315P00007500 OPASPS Put American 100 7.5 BATO 2024-03-15
O:ASXC240315P00005000 OPASPS Put American 100 5 BATO 2024-03-15
O:ASXC240315P00002500 OPASPS Put American 100 2.5 BATO 2024-03-15
O:ASXC240315C00007500 OCASPS Call American 100 7.5 BATO 2024-03-15
O:ASXC240315C00005000 OCASPS Call American 100 5 BATO 2024-03-15
O:ASXC240315C00002500 OCASPS Call American 100 2.5 BATO 2024-03-15
O:ASXC240216P00007500 OPASPS Put American 100 7.5 BATO 2024-02-16
O:ASXC240216P00005000 OPASPS Put American 100 5 BATO 2024-02-16
O:ASXC240216P00002500 OPASPS Put American 100 2.5 BATO 2024-02-16
O:ASXC240216C00007500 OCASPS Call American 100 7.5 BATO 2024-02-16
O:ASXC240216C00005000 OCASPS Call American 100 5 BATO 2024-02-16
O:ASXC240216C00002500 OCASPS Call American 100 2.5 BATO 2024-02-16
O:ASXC240119P00007500 OPASPS Put American 100 7.5 BATO 2024-01-19
O:ASXC240119P00005000 OPASPS Put American 100 5 BATO 2024-01-19
O:ASXC240119P00003500 OPASPS Put American 100 3.5 BATO 2024-01-19
O:ASXC240119P00003000 OPASPS Put American 100 3 BATO 2024-01-19
O:ASXC240119P00002500 OPASPS Put American 100 2.5 BATO 2024-01-19
O:ASXC240119P00002000 OPASPS Put American 100 2 BATO 2024-01-19
O:ASXC240119P00001500 OPASPS Put American 100 1.5 BATO 2024-01-19
O:ASXC240119P00001000 OPASPS Put American 100 1 BATO 2024-01-19
O:ASXC240119P00000500 OPASPS Put American 100 0.5 BATO 2024-01-19
O:ASXC240119C00007500 OCASPS Call American 100 7.5 BATO 2024-01-19
O:ASXC240119C00005000 OCASPS Call American 100 5 BATO 2024-01-19
O:ASXC240119C00003500 OCASPS Call American 100 3.5 BATO 2024-01-19
O:ASXC240119C00003000 OCASPS Call American 100 3 BATO 2024-01-19
O:ASXC240119C00002500 OCASPS Call American 100 2.5 BATO 2024-01-19
O:ASXC240119C00002000 OCASPS Call American 100 2 BATO 2024-01-19
O:ASXC240119C00001500 OCASPS Call American 100 1.5 BATO 2024-01-19
O:ASXC240119C00001000 OCASPS Call American 100 1 BATO 2024-01-19
O:ASXC240119C00000500 OCASPS Call American 100 0.5 BATO 2024-01-19
O:ASXC231215P00007500 OPASPS Put American 100 7.5 BATO 2023-12-15
O:ASXC231215P00005000 OPASPS Put American 100 5 BATO 2023-12-15
O:ASXC231215P00002500 OPASPS Put American 100 2.5 BATO 2023-12-15
O:ASXC231215C00007500 OCASPS Call American 100 7.5 BATO 2023-12-15
O:ASXC231215C00005000 OCASPS Call American 100 5 BATO 2023-12-15
O:ASXC231215C00002500 OCASPS Call American 100 2.5 BATO 2023-12-15
O:ASXC231117P00007500 OPASPS Put American 100 7.5 BATO 2023-11-17
O:ASXC231117P00005000 OPASPS Put American 100 5 BATO 2023-11-17
O:ASXC231117P00002500 OPASPS Put American 100 2.5 BATO 2023-11-17
O:ASXC231117C00007500 OCASPS Call American 100 7.5 BATO 2023-11-17
O:ASXC231117C00005000 OCASPS Call American 100 5 BATO 2023-11-17
O:ASXC231117C00002500 OCASPS Call American 100 2.5 BATO 2023-11-17
O:ASXC231020P00007500 OPASPS Put American 100 7.5 BATO 2023-10-20
O:ASXC231020P00005000 OPASPS Put American 100 5 BATO 2023-10-20
O:ASXC231020P00002500 OPASPS Put American 100 2.5 BATO 2023-10-20
O:ASXC231020C00007500 OCASPS Call American 100 7.5 BATO 2023-10-20
O:ASXC231020C00005000 OCASPS Call American 100 5 BATO 2023-10-20
O:ASXC231020C00002500 OCASPS Call American 100 2.5 BATO 2023-10-20
O:ASXC230915P00007500 OPASPS Put American 100 7.5 BATO 2023-09-15
O:ASXC230915P00005000 OPASPS Put American 100 5 BATO 2023-09-15
O:ASXC230915P00002500 OPASPS Put American 100 2.5 BATO 2023-09-15
O:ASXC230915C00007500 OCASPS Call American 100 7.5 BATO 2023-09-15
O:ASXC230915C00005000 OCASPS Call American 100 5 BATO 2023-09-15
O:ASXC230915C00002500 OCASPS Call American 100 2.5 BATO 2023-09-15
O:ASXC230818P00007500 OPASPS Put American 100 7.5 BATO 2023-08-18
O:ASXC230818P00005000 OPASPS Put American 100 5 BATO 2023-08-18
O:ASXC230818P00002500 OPASPS Put American 100 2.5 BATO 2023-08-18
O:ASXC230818C00007500 OCASPS Call American 100 7.5 BATO 2023-08-18
O:ASXC230818C00005000 OCASPS Call American 100 5 BATO 2023-08-18
O:ASXC230818C00002500 OCASPS Call American 100 2.5 BATO 2023-08-18
News Stream
Calendar Calendar of Events
Asensus Surgical, Inc. Schedules First Quarter Financial and Operating Results Conference Call for May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release 2024 first quarter financial and operating results after the market closes on Tuesday, May 14, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.
GlobeNewswire Inc. • 1w ago
News Product / Services Announcement
Asensus Surgical Announces Sendai Tokushukai Hospital in Japan to Initiate Senhance Surgery Program
Second System to be Utilized by one of the Largest Private Hospital Systems in Japan
GlobeNewswire Inc. • 2w ago
Stocks Mergers and Acquisitions
Asensus Surgical, Inc. Announces Non-Binding Acquisition Proposal and Exclusivity Arrangement with KARL STORZ SE & Co. KG
KARL STORZ to provide up to $20 million in bridge financing KARL STORZ to provide up to $20 million in bridge financing
GlobeNewswire Inc. • 1mo ago
Stocks Earnings Releases and Operating Results
Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter 2023 and Full Year 2023
RESEARCH TRIANGLE PARK, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced its operating and financial results for the fourth quarter and full year 2023.
GlobeNewswire Inc. • 1mo ago
Calendar Calendar of Events
Asensus Surgical, Inc. Schedules Fourth Quarter and Full Year 2023 Financial and Operating Results Conference Call for March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 15, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced today that it plans to release fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, March 21, 2024. The Company will host a conference call to discuss these results starting at 4:30 p.m. ET the same day. The call will be concurrently webcast.
GlobeNewswire Inc. • 2mo ago
Calendar Calendar of Events
Asensus Surgical to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC) announced today that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company’s virtual presentation will take place on Tuesday, March 12, 2024 at 4:40 pm Eastern Time.
GlobeNewswire Inc. • 2mo ago
News Product / Services Announcement
Asensus Surgical Celebrates 1,000 Senhance Cases Completed at Three Global Hospitals
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient, announced the completion of more than 1,000 successful cases each at three hospitals utilizing the Senhance® Surgical System: Klaipeda University Hospital (Lithuania), Presidential Clinic Astana (Kazakhstan), and Evangelisches Krankenhaus Wesel GmbH (Germany).
GlobeNewswire Inc. • 2mo ago
News News
Down -25.24% in 4 Weeks, Here's Why Asensus Surgical (ASXC) Looks Ripe for a Turnaround
Asensus Surgical (ASXC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Research • 3mo ago
News Product / Services Announcement
Asensus Surgical Announces Nagoya University Hospital in Japan to Initiate Senhance Surgery Program
The Fourth Hospital to Initiate a Senhance® Surgical System Dedicated to Pediatric Procedures The Fourth Hospital to Initiate a Senhance® Surgical System Dedicated to Pediatric Procedures
GlobeNewswire Inc. • 4mo ago
Stocks Annual report
Asensus Surgical Provides Preliminary 2023 Year-End Corporate Update
RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and patient, provided a preliminary 2023 year-end corporate update.
GlobeNewswire Inc. • 4mo ago
See All
Related
Latest

Contactez-nous dès aujourd'hui pour découvrir comment notre solution peut vous aider à tirer parti de la puissance des données.

CONTACTER UN EXPERT